Pages that link to "Q34750568"
Jump to navigation
Jump to search
The following pages link to A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines (Q34750568):
Displaying 50 items.
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens (Q26774913) (← links)
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms (Q27692033) (← links)
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential (Q28075927) (← links)
- Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells (Q28487347) (← links)
- Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms (Q31077729) (← links)
- Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. (Q33634389) (← links)
- Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell (Q33741100) (← links)
- Implications of heterogeneity in multiple myeloma (Q33914824) (← links)
- Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. (Q34345502) (← links)
- Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma (Q34364560) (← links)
- Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. (Q34786411) (← links)
- A novel measure of chromosome instability can account for prognostic difference in multiple myeloma (Q34805291) (← links)
- In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells (Q35167162) (← links)
- RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. (Q35187880) (← links)
- Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma (Q35321868) (← links)
- Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway (Q35604566) (← links)
- Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma (Q35944699) (← links)
- European perspective on multiple myeloma treatment strategies: update following recent congresses (Q35989943) (← links)
- Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy (Q36010195) (← links)
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma (Q36413655) (← links)
- A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. (Q36413780) (← links)
- Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma (Q36662044) (← links)
- Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. (Q37083880) (← links)
- Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism (Q37132250) (← links)
- Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma (Q37144899) (← links)
- DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine (Q37408128) (← links)
- TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms (Q37672563) (← links)
- IMWG consensus on risk stratification in multiple myeloma (Q38131380) (← links)
- Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. (Q38394274) (← links)
- Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. (Q38671390) (← links)
- A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma (Q38700339) (← links)
- Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. (Q38712993) (← links)
- The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells (Q38716057) (← links)
- MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma (Q38735514) (← links)
- Identification of pathway-based prognostic gene signatures in patients with multiple myeloma (Q38760910) (← links)
- VOLIN and KJON-Two novel hyperdiploid myeloma cell lines (Q38764103) (← links)
- Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. (Q38808490) (← links)
- In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. (Q38910971) (← links)
- Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. (Q38927737) (← links)
- Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy (Q38949770) (← links)
- RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma (Q38967891) (← links)
- Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. (Q39048347) (← links)
- Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma (Q39158096) (← links)
- PDK1 inhibition is a novel therapeutic target in multiple myeloma (Q39210001) (← links)
- The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. (Q39363181) (← links)
- Gene signature combinations improve prognostic stratification of multiple myeloma patients. (Q40209753) (← links)
- Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells (Q41360812) (← links)
- TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells (Q41819292) (← links)
- Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease (Q41850036) (← links)
- Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients (Q42022337) (← links)